MedPath

The therapeutic effect ofTemozolomide, Vincristine, Interferon-beta and Bevacizumab Combination Chemoradiotherapy for Malignant Gliomas

Phase 2
Recruiting
Conditions
Malignant glioma
Registration Number
JPRN-UMIN000024209
Lead Sponsor
Department of Neurosurgery, Hirosaki University Graduate school of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who did not satisfy inclusion criteria.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
overall survival
Secondary Outcome Measures
NameTimeMethod
progression-free survival, adverse events
© Copyright 2025. All Rights Reserved by MedPath